Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose long-course peginterferon alfa-2b for HBV-related hepatocellular carcinoma
ChiCTR2400082437Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Mar 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in hepatocellular carcinoma (HCC) and Chronic Hepatitis B (CHB) (4 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoint: Overall survival with different treatment regimens (primary) at 48 weeks. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2400082437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082437.